# Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

> **NCT06810050** · PHASE2 · COMPLETED · sponsor: **CAGE Bio Inc.** · enrollment: 180 (actual)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** CGB-500 with 0.5% tofacitinib
- **DRUG:** CGB-500 Ointment with 1% tofacitinib
- **DRUG:** Vehicle (placebo)

## Key facts

- **NCT ID:** NCT06810050
- **Lead sponsor:** CAGE Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-18
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810050, "Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06810050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*